Stablecoin Development Corp (SDEV): Nasdaq/NYSE listing notice — NovaBay receives NYSE American delisting notice for insufficient stockholders' equity

Stablecoin Development Corp

Stockholders' equity was $3.3M as of Dec 31, 2023, below $4M and $6M thresholds.
Must submit compliance plan by May 18, 2024; regain compliance by Oct 18, 2025 to avoid delisting.
Trading continues with '.BC' indicator appended to ticker; no immediate impact on operations.
Company intends to submit a plan to NYSE American within prescribed timeframe.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Stablecoin Development Corp received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii), 1003(a)(iii)).

Exchange: nyse american
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 1003(a)(ii), 1003(a)(iii)

Exact text from the filing

April 18, 2024, NovaBay Pharmaceuticals, Inc. (the “ Company ”) received a notification (“ Deficiency Letter ”) from the NYSE American LLC (the “ NYSE American ”) stating that the Company is not in compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the “ Company Guide ”) requiring stockholders’ equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses

View on SEC.gov

94 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Stablecoin Development Corp filing history →

Source: SEC EDGAR

accession 0001437749-24-012586

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.